Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-25 @ 9:36 PM
Study NCT ID:
NCT00387751
Status:
COMPLETED
Last Update Posted:
2017-11-22
First Post:
2006-10-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-08
Start Date Type:
ACTUAL
Primary Completion Date:
2009-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-01
Completion Date Type:
ACTUAL
First Submit Date:
2006-10-12
First Submit QC Date:
None
Study First Post Date:
2006-10-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-12-07
Results First Submit QC Date:
None
Results First Post Date:
2013-01-17
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-10-19
Last Update Post Date:
2017-11-22
Last Update Post Date Type:
ACTUAL